The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review

Roberto Carando, Luca Afferi, Giancarlo Marra, Wojciech Krajewski, Vincenzo Pagliarulo, Mohammad Abufaraj, Evangelos Xylinas, Xavier Cathelineau, Rafael Sanchez-Salas & Marco Moschini

To cite this article: Roberto Carando, Luca Afferi, Giancarlo Marra, Wojciech Krajewski, Vincenzo Pagliarulo, Mohammad Abufaraj, Evangelos Xylinas, Xavier Cathelineau, Rafael Sanchez-Salas & Marco Moschini (2020): The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review, Arab Journal of Urology, DOI: 10.1080/2090598X.2020.1733818

To link to this article: https://doi.org/10.1080/2090598X.2020.1733818

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 01 Mar 2020.

Article views: 121

View related articles

View Crossmark data
The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (VESICAL IMAGING-REPORTING AND DATA SYSTEM): A systematic review

Roberto Carando,1,2,3,4,5 Luca Afferi,6 Giancarlo Marra,7 Wojciech Krajewski,8 Vincenzo Pagliarulo,9 Mohammad Abufaraj10, Evanguelos Xylinas,11 Xavier Cathelineau,1 Rafael Sanchez-Salas1 and Marco Moschini1,2

Abstract

Objective: To evaluate the role of the Vesical Imaging-Reporting and Data System (VI-RADS) score in the diagnostic pathway of bladder cancer.

Methods: A systematic search of the contemporary literature was performed in December 2019 using the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica database (EMBASE), and Web of Science databases focusing on all available articles on VI-RADS.

Results: Overall, six of 15 articles were included. All the available articles evaluated the ability of radiologists to use the VI-RADS score for discriminating non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC). Considering a cut-off VI-RADS score of >2, the sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were 78–91.9%, 85–91%, 69–78%, and 88–97.1%, respectively. Considering a VI-RADS score cut-off of >3, the sensitivity, specificity, PPV and NPV were 77–94.6%, 43.9–96.5%, 51.6–86%, and 63.7–93%, respectively. Good interobserver agreement was demonstrated in the evaluated studies with a κ score of 0.73–0.89. Only one study evaluated the utility of VI-RADS in determining the presence of MIBC in patients treated with transurethral resection of the bladder diagnosed with high-grade T1 before the second transurethral resection using a VI-RADS score cut-off of >2; the sensitivity, specificity, PPV and NPV were 85%, 93.6%, 74.5%, and 96.6%, respectively.

Conclusion: The VI-RADS score, using multiparametric magnetic resonance imaging, showed excellent results in discriminating MIBC from NMIBC. Preliminary results have been reported for its use in patients with high-grade T1 bladder cancer. These results need to be validated in high-quality real-world settings.

Abbreviations: DCE: dynamic contrast enhancement; DWI: diffusion-weighted imaging; (N)MIBC: (non-)muscle-invasive bladder cancer; mpMRI: multiparametric MRI; TURBT: transurethral resection of bladder tumour; (N)(P)PV: (negative) (positive) predictive value; SC: structural category; T2W: T2-weighted; VI-RADS: vesical imaging-reporting and data system

Introduction

Multiparametric MRI (mpMRI) has been widely adopted in diagnosing and risk-stratifying prostate cancer [1], and shown promising results in differentiating cystic renal masses [2]. Recently, its use has been proposed in the diagnostic pathway of bladder cancer with the development of the Vesical Imaging-Reporting and Data System (VI-RADS) score [3].

Clinical management of bladder cancer is currently determined mainly based on clinical T Stage determination using transurethral resection of bladder tumour (TURBT) as a diagnostic and therapeutic surgical tool [4]. By reporting tumour invasion at the time of TURBT, urologists are able to decide whether to proceed with radical cystectomy, a morbid procedure associated with impaired quality of life [5–7], or in the case of non-muscle-invasive bladder cancer (NMIBC) to treat the tumour with less invasive methods, such as TURBT followed by adjuvant intravesical instillation. In this regard, TURBT is not a perfect diagnostic and therapeutic tool, with an up to 50% residual tumour rate and 10% progression rate diagnosed at re-TURBT [8]. These rates depend on surgical experience and tumour characteristics.

The use of mpMRI has been proposed to increase the preoperative diagnostic ability in differentiating NMIBC and MIBC to improve the effectiveness of TURBT. The aim of the present systematic review was to summarise the current evidence on the VI-RADS, and its possible implications and future directions in the management of patients with bladder cancer.
Methods

A systematic literature review was performed in December 2019 using the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica database (EMBASE), and Web of Science databases. Review articles, editorials and congress abstracts were excluded. Search terms included ‘VI-RADS’ in combination or alone with the terms ‘radical cystectomy’ OR ‘bladder cancer’ OR ‘transurethral resection’. The search was limited to the English literature. References cited in selected articles and in review articles retrieved in our search were also used to identify manuscripts that were not included in the initial searches. The articles that provided the highest level of evidence were then evaluated, where existing prospective studies were preferred to retrospective designs. A list of articles judged to be highly relevant by the first and senior authors was circulated amongst the co-authors and a final consensus was reached on the structure of the review and the articles included. The systematic review was performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [9] (Figure 1).

The development of VI-RADS

Although several articles exist supporting the role of mpMRI in patients with bladder cancer [10,11], the first description of the VI-RADS score was performed by Panebianco et al. [3] in 2018. A multidisciplinary team composed of members from Europe, North America, South America and Asia with a Delphi-like consensus protocol proposed a 5-point score. The risk of muscle invasion was to be assessed using T2-weighted (T2W) MRI, diffusion-weighted imaging (DWI), and dynamic contrast enhancement (DCE). Considering patient selection and preparation, the authors recognised that previous TURBT and intravesical instillation might cause oedema of the bladder wall, which can be confused with tumour invasion, resulting in overestimation of local stage. Therefore, similarly to prostate cancer (with regards to prostate biopsies), MRI examination should be performed before or ≥2 weeks after TURBT or intravesical instillation [12]. Additionally, gas collections (bubbles) in the bladder can cause distortion of the imaging and therefore a 3-day interval between cystoscopy or removal of a catheter and MRI is recommended. The patient should be prepared with the use of an antispasmodic agent to minimise artefacts from bowel peristalsis [13]. The bladder should be distended, and patients should be instructed to not void 1–2 h before imaging or to start drinking 500–1000 mL water in the 30 min before the examination. No distention, as well as overdistension, might lead to a misdiagnosis or over staging of any tumours that are present. Optimally, the bladder should contain ~300 mL at the time of the MRI [14].

From a technical point of view, MR equipment of 1.5 or 3.0 T is recommended to achieve high spatial

Figure 1. Flow diagram of the search results.
resolution and signal-to-noise ratio. The T2W image, DWI and DCE MRI are key components of the mpMRI examination. All images should include the whole bladder, proximal urethra, pelvic nodes and prostate if the patient is a male. In females, uterus, ovaries, fallopian tubes and vagina should be included. A spin-echo T1-weighted image can be used in cases of haemorrhage and clots in the bladder or bone metastases. A detailed technical explanation can be found in the original article from Panebianco et al. [3].

The 5-point VI-RADS score is finally created using the individual structural category (SC), diffusion-weighted (DW) category, and contrast-enhanced (CE) category from T2W, DWI and DCE MRI to predict the probability of muscle invasion. With a VI-RADS 1 score, muscle invasion is highly unlikely: SC, CE and DW category 1. With a VI-RADS 2 score, muscle invasion is unlikely to be present: SC, CE and DW category 2, both CE and DW category 2 with SC category 3. VI-RADS 3 score, presence of muscle invasion is equivocal: SC, CE and DW category 3, or SC category 3 CE or DW category 3, the remaining sequence category 2. VI-RADS 4 score, muscle invasion is likely: at least SC and/or DW and/or CE category 4, the remaining category 3; VI-RADS 5 score, invasion of muscle and beyond the bladder is very likely: at least SC plus DW and/or CE category 5, the remaining category 4 or 5.

Results

The effectiveness of mpMRI in differentiating NMIBC from MIBC

An overview of the published studies evaluating the ability of VI-RADS to discriminate NMIBC from MIBC is presented in Table 1 [15–20]. Differentiating NMIBC and MIBC is crucial for counselling patients with bladder cancer. Surgical management of NMIBC and MIBC is completely different and using mpMRI to differentiate it might reduce costs and perioperative complications. Different results were obtained considering different VI-RADS cut-offs, when considering a cut-off VI-RADS score of 2, sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were 78–91.9%, 85–91.1%, 69–78%, and 88–97.1%, respectively. Considering a cut-off of VI-RADS >3, sensitivity, specificity, PPV and NPV were 77–94.6%, 43.9–96.5%, 51.6–86%, and 63.7–93%, respectively. Considering a cut-off of VI-RADS >4, sensitivity, specificity, PPV and NPV were 76–91%, 76–93%, 83.3%, and 78.9%, respectively.

Most published studies had more than one radiologist included and inter-observer agreement analyses were performed with k statistics, in order to evaluate the variability of radiologists’ evaluation of mpMRI with the VI-RADS score. Overall, good inter-observer agreement was found with a k score ranging between 0.73 and 0.89. To date, Del Giudice et al. [15] is the only prospective evaluation, they used a VI-RADS score cut-off of 1–2 vs 2–5 to differentiate superficial from invasive disease at TURBT. Further data are required to validate these findings in real-world settings.

Potential limitations of the VI-RADS score

Although these preliminary results (Table 1) showed that the VI-RADS score can play an important role in the diagnostic pathway of patients with bladder cancer, still some limitations need to be highlighted and discussed. First, inter-observer disagreement has been reported in the existing literature [15–19]. There is an urgent need to evaluate the VI-RADS score in real-world settings to ensure that even in non-tertiary referral centres, this system can offer the same results as those described by experienced radiologists. Second, some pathological parameters cannot be assessed by imaging such as carcinoma in situ, lymphovascular invasion, and the presence of histological variants, which play an important role in determining the optimal therapeutic and prognostic management of patients with bladder cancer [21–23]. Third, the new molecular classification of the bladder cancer [24], although still not clinically validated has already shown promising results in determining the necessity of chemotherapy, radiation therapy or immunotherapy. Still, the presence of an accurate pathological evaluation is still necessary for individualised therapy [25].
Table 1. Studies reporting results of VI-RADS.

| Reference            | Patients, \( n \) | Years of accrual | Aim                                                                 | Sensitivity, % | Specificity, % | PPV, % | NPV, % | AUC | Number of observers, inter-observer agreement |
|----------------------|-------------------|------------------|----------------------------------------------------------------------|----------------|----------------|--------|--------|-----|------------------------------------------------|
| Barchetti et al. 2019 [19] | 75               | 2017–2018        | Evaluate accuracy and inter observer variability using VI-RADS for discrimination between NMIBC and MIBC | Reader 1: 91 (VI-RADS >2) Reader 2: 82 (VI-RADS >2) Reader 2: 1.82 (VI-RADS >3) Reader 2: 77 (VI-RADS >3) | Reader 1: 89 (VI-RADS >2) Reader 2: 85 (VI-RADS >2) Reader 1: 94 (VI-RADS >3) Reader 2: 89 (VI-RADS >3) | Reader 1: 77 (VI-RADS >2) Reader 2: 69 (VI-RADS >2) Reader 1: 86 (VI-RADS >3) Reader 2: 74 (VI-RADS >3) | Reader 1: 89 (VI-RADS >2) Reader 2: 92 (VI-RADS >2) Reader 1: 93 (VI-RADS >3) Reader 2: 91 (VI-RADS >3) | Reader 1: 0.93 Reader 2: 0.87 | 2, Inter-observer agreement for the overall score: \( \kappa = 0.731 \) |
| Del Giudice et al. 2019 [15] | 231              | 2017–2019        | 1. Differentiation between NMIBC and MIBC 2. Avoiding second TUR after TUR in H-R NMIBC | Reader 1: 91.9 (VI-RADS >2) Reader 2: 85 (VI-RADS >2) | Reader 1: 91.1 (VI-RADS >2) Reader 2: 93.6 (VI-RADS >2) | Reader 1: 77.5 (VI-RADS >2) Reader 2: 74.5 (VI-RADS >2) | Reader 1: 97.1 (VI-RADS >2) Reader 2: 96.6 (VI-RADS >2) | Reader 1: 0.94 Reader 2: 0.93 | 2, \( \kappa = 0.81 \) |
| Makboul et al. 2019 [16] | 50               | n.r.             | Differentiation between NMIBC and MIBC | 78 (VI-RADS >2) 88 (VI-RADS >2) | 78 (VI-RADS >2) 88 (VI-RADS >2) | 78 (VI-RADS >2) 88 (VI-RADS >2) | 78 (VI-RADS >2) 88 (VI-RADS >2) | 2, \( \kappa = 0.87 \) |
| Kim et al. 2019 [17]   | 297              | 2015–2019        | Differentiation between NMIBC and MIBC | 91.3 (VI-RADS >4) 94.6 (VI-RADS >3) | 76 (VI-RADS >4) 43.9 (VI-RADS >3) | 83.3 (VI-RADS >4) 51.6 (VI-RADS >3) | 78.9 (VI-RADS >4) 63.7 (VI-RADS >3) | n.r. | 2, \( \kappa = 0.89 \) for T2 W, \( \kappa = 0.82 \) for DWI, and \( \kappa = 0.88 \) for DCE |
| Wang et al. 2019 [18]  | 340              | 2011–2018        | Differentiation between NMIBC and MIBC | 87.1 (VI-RADS >3) 96.5 (VI-RADS >3) | n.r. | n.r. | 0.94 | n.r. |
| Ueno et al. 2019 [20]  | 74               | 2010–2018        | Differentiation between NMIBC and MIBC | 76 (VI-RADS >4) 88 (VI-RADS >3) | 93 (VI-RADS >4) 77 (VI-RADS >3) | n.r. | n.r. | 0.90 | 5, Interclass correlation coefficient: 0.85 |

AUC: area under the curve; H-R: high-risk; n.r.: not reported.
Therefore, MRI staging based on the VI-RADS classification may be useful in daily practice but does not give an overview of the tumour’s biology.

Conclusion

The VI-RADS score showed excellent results in discriminating MIBC from NMIBC. Preliminary results confirmed similar findings in patients diagnosed with high-grade T1 NMIBC candidates for a second TURBT. Although some limitation exists, such as the absence of pathological specimen for evaluation of morphological and genomic prognostic factors, the VI-RADS score seems a promising tool in the diagnostic pathway of bladder cancer.

Disclosure Statement

The authors declare that they have no conflicts of interest.

ORCID

Marco Moschini http://orcid.org/0000-0002-3084-2458

References

[1] Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. Eur Urol. 2019;75:385–396.
[2] Ferreira AM, Reis RB, Kajiwara PP, et al. MRI evaluation of complex renal cysts using the Bosniak classification: a comparison to CT. Abdom Radiol. 2016;41:2011–2019.
[3] Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74:294–306.
[4] Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
[5] Moschini M, Simone G, Stenzl A, et al. Critical review of outcomes from radical cystectomy: can complications from radical cystectomy be reduced by surgical volume and robotic surgery? Eur Urol Focus. 2016;2:19–29.
[6] Tourinho-Barbosa RR, Tobias-Machado M, Castro-Alfaro A, et al. Complications in robotic urological surgeries and how to avoid them: A systematic review. Arab J Urol. 2018;16:628–292.
[7] Rangarajan K, Somani BK. Trends in quality of life reporting for radical cystectomy and urinary diversion over the last four decades: A systematic review of the literature. Arab J Urol. 2019;17:181–194.
[8] Cumberbatch MG, Foerster B, Catto JW, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73:925–933.
[9] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
[10] de Haas RJ, Steyvers MJ, Fütt erer JJ. Multiparametric MRI of the bladder: ready for clinical routine? Am J Roentgenol. 2014;202:1187–1195.
[11] Moschini M, Morlacco A, Briganti A, et al. Clinical lymphadenopathy in urothelial cancer: a transatlantic collaboration on performance of cross-sectional imaging and oncologic outcomes in patients treated with radical cystectomy without neoadjuvant chemotherapy. Eur Urol Focus. 2018;4:245–251.
[12] Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994;193:239–245.
[13] Johnson W, Taylor MB, Carrington BM, et al. The value of hyoscine butylbromide in pelvic MRI. Clin Radiol. 2007;62:1087–1093.
[14] Panebianco V, Barchetti F, de Haas RJ, et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus. 2016;2:113–121.
[15] Del Giudice F, Barchetti G, De Berardinis E, et al. Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non–muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol. 2020;77:101–109.
[16] Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019;92:20190401.
[17] Kim SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY). 2020;45:491–498.
[18] Wang H, Luo C, Zhang F, et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion. Radiology. 2019;291:668–674.
[19] Barchetti G, Simone G, Ceravolo I, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol. 2019;29:5498–5506.
[20] Ueno Y, Takeuchi M, Tamada T, et al. Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: a multireader validation study. Eur Urol. 2019;76:54–56.
[21] Aziz A, Shariat SF, Roghmann F, et al. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int. 2016;117:272–279.
[22] Moschini M, D’Andrea D, Korn S, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14:651–668.
[23] Moschini M, Shariat SF, Abufraraj M, et al. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: implications for follow-up schemes. Urol Oncol. 2017;35:151.e17–151.e23.
[24] Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2019;76:54–56. Epub ahead of print. DOI:10.1016/j.eururo.2019.09.006.
[25] Seiler R, Ashab HA, Ethro N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72:544–554.